Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

39.27 +0.24 (+0.61%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
24 25 Next >
Arcus, Gilead Disappoint As Lung-Cancer Regimen Lags Rival Roche
Gilead and Arcus toppled Tuesday after their lung-cancer regimen trailed a rival concoction from Roche. 
Via Investor's Business Daily
OTC Market Group's Most Active List In November: A Dive Into The Names Experiencing Volume Changes
The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) increased by 5.56% in November, recording two subsequent monthly increases for the first time in 2022. 
Via Benzinga
Roche Presents New Data Demonstrating Potential Benefit Of Two Lymphoma Candidates
Via Benzinga
Broadcom-Vmware Deal Draws European Regulatory Attention, Rivian Pauses Mercedes-Partnered EV Van Plans For Europe, Credit Suisse Issued Loan On Suspicious Bills: Top Stories Monday, Dec. 12
Reuters Broadcom's Vmware Draws More Regulatory Attention, This Time From EU 
Via Benzinga
After 16 Years, Roche's Pharma Division Head Decides To Step Down
Via Benzinga
Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting
Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study  
Via Benzinga
3 Hot Stocks That Could Live Up to Their Lofty Valuations
These companies have long runways of growth ahead 
Via The Motley Fool
Replimune Shares Surge After Early Data From Pretreated Melanoma Patients
Via Benzinga
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%. 
Via Benzinga
Gilead's Cancer Program Notches Another Win, But It's Arcus Stock That Surges
Gilead and Arcus notched another win for their cancer program on Monday. GILD stock briefly hit a four-year high as RCUS stock gapped higher. 
Via Investor's Business Daily
This Congressman Just Purchased 2 Stocks Which Consistently Increase Dividends
Congressman Dwight Evans (D-PA) has represented Pennsylvania's Third Congressional District since 2019, and has made over 70 trades in the past three years. His top two traded investments are Intel... 
Via Benzinga
Daily Stock Analysis: Roche Holding
By my dogcatcher ideal, this is not a good time to buy Roche Holding AG shares based on their dividends for the coming year 2022-23. 
Via Talk Markets
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm
Neurodegenerative disorders could mean big bucks for some biotechs. 
Via Investor's Business Daily
Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says
Via Benzinga
FDA Gives Emergency Use Nod To Roche's Monkeypox Test
Via Benzinga
Successful Alzheimer's Data Would Have Placed Roche At Two-Year Competitive Advantage
Via Benzinga
Roche Inks Second Drug Discovery Deal With Jnana Therapeutics
Via Benzinga
FDA Grants Conditional Approval To First Antibody Drug Conjugate From ImmunoGen For Pretreated Ovarian Cancer
Via Benzinga
Why Is Cassava Sciences (SAVA) Stock Up Today?
Today's big move in Cassava Sciences and SAVA stock has many investors watching this company's trials closer than ever. 
Via InvestorPlace
Eli Lilly's Twitter Fiasco Continues As Drugmaker Reportedly Pulls 'Millions' In Twitter Ads
The fallout from a fake account continued Monday as Lilly reportedly pulled Twitter ads. 
Via Investor's Business Daily
Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers
Via Benzinga
Why Is Biogen (BIIB) Stock Up Today?
Biogen (BIIB) stock is rising higher on Monday after Roche's (RHHBY) Alzheimer's drug didn't perform well in a clinical trial. 
Via InvestorPlace
Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And Others
Biogen rose on Roche's Alzheimer's failure as a potential competitor drops off the map. 
Via Investor's Business Daily
The OTCQB Venture Market Records 4 Months Of Consecutive Volume Increases In OTC Market Group's Most-Active List In October
The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) increased by 8.13% in October — its second-largest monthly increase in 2022. 
Via Benzinga
Roche's Another Alzheimer's Hopeful Flops In Phase 3 Program, Second Trial Setback Within Months
Via Benzinga
Nasdaq, S&P 500 Futures Pullback At Start Of New Trading Week As Rate Fears Return To Haunt; AMD, Tesla, Biogen, Eli Lilly, JD In Focus
The major U.S. index futures are pointing to a moderately lower opening on Wall Street on Monday, as optimism following a tamer inflation data gives way to apprehension. The yield on the benchmark... 
Via Benzinga
Why Shares Of Eli Lilly And Biogen Are Rallying Today
Shares of Biogen Inc. (NASDAQ: BIIB) and Eli Lilly & Co. (NYSE: LLY) are rallying in premarket trading on Monday despite the negative broader market sentiment. 
Via Benzinga
6 ETFs That Are All You Need for Retirement
These yield-producing stock and bond funds are all down less than the S&P 500 this year. 
Via The Motley Fool
15 Global Psychedelics Executives To Keep An Eye On In 2022
As the global psychedelics industry booms, with companies going public, major financings being announced, and celebrities and big investors getting on board, Benzinga has decided to put together a list... 
Via Benzinga
Most Active On The OTC Markets In September – A Look Back As October Comes To A Close
By Jad Malaeb, Benzinga 
Via News Direct
Topics ETFs Stocks
Exposures US Equities
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
24 25 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.